I-Mab Reports 1H 2024 Financial Results, Pipeline Progress, and ...
I-Mab announced financial results and pipeline progress, including IND clearance for uliledlimab, a collaboration with Bristol Myers Squibb for givastomig, and promising early data for ragistomig. With $207.5 million in cash, the company is well-positioned for pipeline advancement, expecting cash runway into 2027.
Reference News
I-Mab Reports 1H 2024 Financial Results, Pipeline Progress, and ...
I-Mab announced financial results and pipeline progress, including IND clearance for uliledlimab, a collaboration with Bristol Myers Squibb for givastomig, and promising early data for ragistomig. With $207.5 million in cash, the company is well-positioned for pipeline advancement, expecting cash runway into 2027.